Advertisement

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Advertisement

Advertisement

Feb

24

Today In Oncology

MRI-Based Neoadjuvant Chemotherapy Duration in HER2-Positive Breast Cancer

Can a New Testing Method Allow More Patients With Bladder Cancer to Avoid Radical Cystectomy

Adjuvant Coformulated Vibostolimab Plus Pembrolizumab in High-Risk Stage IIB to IV Melanoma

Microplastics Found in 90 Percent of Prostate Cancer Samples

Proximity to Nuclear Power Plants and Cancer Risk

Advertisement

© 2026 HSP News Service, L.L.C.